Watch Now!

Catherine Hall, VP Product Strategy at endpoint Clinical tells the story of the past of Direct to Patient Distribution and speculates on the future at Direct-to-Patient and Virtual, Decentralized, and Hyper Clinical Trials. Learning from the evolution of technology and trial design to address the barriers of Direct to Patient and how COVID-19 is reshaping the future of decentralized trials.

What you will learn:

  • History of DTP​
  • How COVID-19 has accelerated adoption of DTP​
  • The evolution of Decentralized Trials and impact on Technology​
  • How the total clinical eco-system will continue to evolve​

Contact us to discuss this topic further.

Cat HallCatherine Hall, VP of Product Strategy, endpoint Clinical

Cat Hall started her career as an academic scientist in Molecular and Cellular Biology before finishing her MBA and transitioning into Pharmaceutical Supply Chain Management. During her career, she developed notable expertise not only in clinical supplies but also in training development, process improvement, managing partnerships, and the design and implementation of technologies such as Interactive Response Technology (IRT).  She is well-known for focusing on bridging the GMP/GCP gap by bringing supply chain customer service through the last mile to patients. Cat joined endpoint in 2019 as VP of Product Strategy to help continue to bring the customer voice forward into shaping the future of IRT.

IndustryPOINTS: Connecting & Educating the Life Sciences Industry


Watch Now!

  By checking this box, I agree to receive periodic email newsletters and updates from endpoint and agree to this privacy policy.